An independent two-stage DCF analysis by a frontier AI model.
" data-astro-cid-mrpccrzy> Stryker's revenue grew over 11% in FY2025, supported by strong demand in MedSurg and Neurotechnology. FCF growth was highly volatile historically but has robust momentum now. 11% reflects expected continued growth driven by Mako robot placements, an aging population, and M&A integration.
" data-astro-cid-mrpccrzy> Stryker's revenue grew over 11% in FY2025, supported by strong demand in MedSurg and Neurotechnology. FCF growth was highly volatile historically but has robust momentum now. 11% reflects expected continued growth driven by Mako robot placements, an aging population, and M&A integration.
" data-astro-cid-mrpccrzy> Stryker's revenue grew over 11% in FY2025, supported by strong demand in MedSurg and Neurotechnology. FCF growth was highly volatile historically but has robust momentum now. 11% reflects expected continued growth driven by Mako robot placements, an aging population, and M&A integration.
Intrinsic value per share under varying discount rate and terminal growth rate assumptions.
| WACC ↓ / Terminal → | 7.0% | 7.5% | 8.0% | 8.5% | 9.0% |
|---|---|---|---|---|---|
| 7.0% | $25.10 | $25.10 | $25.10 | $25.10 | $25.10 |
| 7.5% | $25.10 | $25.10 | $25.10 | $25.10 | $25.10 |
| 8.0% | $25.10 | $25.10 | $25.10 | $25.10 | $25.10 |
| 8.5% | $25.10 | $25.10 | $25.10 | $25.10 | $25.10 |
| 9.0% | $25.10 | $25.10 | $25.10 | $25.10 | $25.10 |
■ Undervalued vs current price ■ Overvalued vs current price
Stryker commands a highly entrenched position within the medical technology industry, supported by substantial switching costs and an extensive portfolio of vital surgical equipment and implants. Its robust Mako robotic-arm assisted surgery platform provides a significant competitive moat and drives long-term recurring revenue. Despite a somewhat leveraged balance sheet, consistent double-digit revenue growth and strong cash flow generation underpin a solid prospect profile. Continuous innovation and strategic acquisitions will likely sustain its market leadership.
Stryker maintains strong top-line momentum driven by consistent volume growth in both MedSurg and Orthopaedics segments.
High switching costs for surgical equipment and a formidable intellectual property portfolio provide a durable economic moat.
Management's consistent execution and a steady pipeline of new product launches support positive sentiment, though valuation remains a consideration.
Gemini 3.1. "Stryker Corporation (SYK) Intrinsic Value: A DCF Analysis." westmountfundamentals.com, March 18, 2026.
Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.